Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Purchased by McGuire Investment Group LLC

McGuire Investment Group LLC boosted its holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 3.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,109 shares of the company’s stock after purchasing an additional 1,940 shares during the quarter. McGuire Investment Group LLC owned approximately 0.83% of Global X Genomics & Biotechnology ETF worth $564,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Oxinas Partners Wealth Management LLC bought a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter valued at $103,000. Atria Investments Inc bought a new stake in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at about $122,000. Centaurus Financial Inc. bought a new stake in shares of Global X Genomics & Biotechnology ETF during the second quarter valued at about $146,000. Rockefeller Capital Management L.P. bought a new stake in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at about $205,000. Finally, James J. Burns & Company LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 6.0% during the third quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock valued at $207,000 after purchasing an additional 1,038 shares in the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Down 1.1 %

Shares of NASDAQ GNOM opened at $10.18 on Friday. Global X Genomics & Biotechnology ETF has a fifty-two week low of $9.50 and a fifty-two week high of $12.53. The firm’s 50-day simple moving average is $10.14 and its 200 day simple moving average is $10.74. The stock has a market cap of $70.95 million, a P/E ratio of -4.35 and a beta of 1.03.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.